Clinical Trials on Stage IIIB Non-Small Cell Lung Cancer in China

Total 1946 results

Sun Yat-sen University

Recruiting

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Non-small Cell Lung Cancer

China
Shanghai Henlius Biotech

Recruiting

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Non Small Cell Lung Cancer

China
Fudan University
Allist Pharmaceuticals, Inc.

Recruiting

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Non-Small-Cell Lung Cancer

China
Hutchison Medipharma Limited

Recruiting

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification (SACHI)

Non-small Cell Lung Cancer

China
Beijing Cancer Prevention & Treatment Society
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib (FLAME)

Non Small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Non Small Cell Lung Cancer

China
Ethicon Endo-Surgery

Completed

Powered Surgical Stapler in VATS Lung Resection Procedures in China

Non-small Cell Lung Cancer

China
Fudan University

Unknown

Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC

Non Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital

Unknown

Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy

Non Small Cell Lung Cancer

China
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-small-cell Lung Cancer

China
Zhejiang Cancer Hospital

Recruiting

Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC

Extensive Stage Lung Small Cell Cancer

China
The First Affiliated Hospital of Xinxiang Medical...

Recruiting

Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients (AP)

Lung Cancer | Non Small Cell Lung Cancer | Lung Carcinoma | Non-small Cell Carcinoma | Lung Neoplasm

China
Guangzhou University of Traditional Chinese Medicine
Akeso Pharmaceuticals, Inc.

Recruiting

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
Qianfoshan Hospital

Recruiting

First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial (FTANLCNDG)

Non-Small-Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Recruiting

Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD

Non Small Cell Lung Cancer

China
Tang-Du Hospital

Recruiting

Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

Non-small Cell Lung Cancer

China
Henan Cancer Hospital

Recruiting

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Hebei Medical University Fourth Hospital

Recruiting

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
The Second Affiliated Hospital of Shandong First...

Recruiting

Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy

Non-small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Yongchang Zhang
Hunan Province Tumor Hospital

Recruiting

A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC (ACROSS1)

Non Small Cell Lung Cancer

China
Li Zhang, MD

Not yet recruiting

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Non-small Cell Lung Cancer

China
Sun Yat-sen University
Tianjin Hengjia Biotechnology Development co., LTD

Recruiting

Phase I Study of Individualized Neoantigen Peptides in the Treatment of EGFR Mutant Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer (ATHENA)

Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Second Xiangya Hospital of Central South University

Enrolling by invitation

A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC

Non-small Cell Lung Cancer

China
Yongchang Zhang

Completed

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Hao Long

Active, not recruiting

Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer (NeoTAP01)

Non Small Cell Lung Cancer

China
First Hospital of Shijiazhuang City
Tianjin Hengjia Biotechnology Development co., LTD

Unknown

Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Non-small Cell Lung Cancer

China
Sun Yat-sen University
Guangzhou Bio-gene Technology Co., Ltd.

Unknown

Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Guangdong Association of Clinical Trials

Terminated

Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation (INNOVATE)

Non-small-cell Lung Cancer

China
Qilu Hospital of Shandong University

Unknown

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer (TCL-1)

Non-Small-Cell Lung Cancer

China
People's Hospital of Guangxi

Unknown

Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Withdrawn

CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Unknown

Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Xinjiang Medical University

Unknown

Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB

Non-small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Unknown

Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)

Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in Locally Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Dizal Pharmaceuticals

Recruiting

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Non-small Cell Lung Cancer

China
Nanfang Hospital, Southern Medical University

Recruiting

An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore

Non-small Cell Lung Cancer

China

3

Subscribe